Literature DB >> 3582463

The influence of antituberculosis drugs on the plasma level of verapamil.

J Mooy, R Böhm, M van Baak, J van Kemenade, A vd Vet, K H Rahn.   

Abstract

The influence of antituberculosis drugs on the plasma level of verapamil was studied after its oral and intravenous administration. Six patients who had been treated for at least 6 months with a combination of rifampicin, ethambutol and isoniazid received a single oral dose of 40 mg verapamil. As compared to untreated subjects, the antituberculosis drugs greatly reduced the bioavailability of the calcium antagonist. Studies in patients in whom treatment with ethambutol and isoniazid had been discontinued revealed that the effect was due to rifampicin. The drugs for tuberculosis had no influence on the plasma level of verapamil when it was given intravenously. The findings can be explained by the induction of verapamil metabolizing liver enzymes in patients treated with rifampicin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582463     DOI: 10.1007/bf00609969

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Interaction of ketoconazole with rifampin and isoniazid.

Authors:  D Engelhard; H R Stutman; M I Marks
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

3.  Pharmacokinetics of verapamil in patients with renal failure.

Authors:  J Mooy; M Schols; M v Baak; M v Hooff; A Muytjens; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The metabolism of DL-[14C]verapamil in man.

Authors:  M Eichelbaum; M Ende; G Remberg; M Schomerus; H J Dengler
Journal:  Drug Metab Dispos       Date:  1979 May-Jun       Impact factor: 3.922

Review 5.  Rifampin drug interactions.

Authors:  A M Baciewicz; T H Self
Journal:  Arch Intern Med       Date:  1984-08

Review 6.  Calcium antagonists. Pharmacokinetic properties.

Authors:  R E Kates
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

  6 in total
  7 in total

1.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Authors:  Shashank Gupta; Sandeep Tyagi; Deepak V Almeida; Mariama C Maiga; Nicole C Ammerman; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 4.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 6.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 7.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.